Short interest for Eliem Therapeutics gives investors a sense of the degree to which investors are betting on the decline of Eliem Therapeutics's stock. Short interest data is updated every two weeks.

Eliem Therapeutics Stock (NASDAQ:ELYM), Short Interest Report

Eliem Therapeutics

Eliem Therapeutics Inc is a clinical-stage biotechnology company. It is focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems. Its main drug candidate is ETX-155 for major depressive disorder (MDD) and focal onset seizures (FOS).

Image45

News

Intraday Update

Markets

Movers

ADXN

AGBA

AKLI

ARCB

Bakkt Holdings, Inc. Class A Common Stock

BKKT

BLND

CECO

CETX

CHGG

COUR

CSLR

CYCC

DARE

EGOX

ELYM

ETWO

FFIV

GEHC

HEES

HLIT

LICN

MIND

MRIN

MSTR

MULN

NIVF

NRXP

RMBS

SGBX

SWVL

TREE

UAVS

VNCE

YUMC

Why H&amp;E Equipment Services Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

Earnings

Penny Stocks

Eurozone

Commodities

Small Cap

Global

Trading Ideas

APVO

ENLV

RCEL

RENT

RLYB

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite surging more than 250 points on Thursday.

The Dow traded up 0.18% to 38,532.50 while the NASDAQ rose 1.63% to 16,433.83. The S&amp;P 500 also rose, gaining, 0.83% to 5,203.26.

Nasdaq Jumps 250 Points; Crude Oil Down 1%

ACOR

AKAN

ALPN

ANAB

CADL

CLRO

ELVN

ESPR

FAST

GYRE

ICCT

JANX

LOVE

NKLA

NRIX

NYXH

SLNA

SPRC

STEP

SUUN

VBIV

VERB

Shares of  Fastenal Company (NASDAQ: FAST) fell sharply during Thursday’s session following worse-than-expected first-quarter financial results.

Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday&#39;s Mid-Day Session

Eliem Therapeutics Inc

Buybacks

WAFD

WaFd Board Increased Number Of Shares Authorized For Repurchase By 10M

WIIM

VTSI

VirTra shares are trading lower after the company reported worse-than-expected Q1 financial results.

DLPN

Dolphin Entertainment shares are trading higher after the company reported a year-over-year increase in Q1 financial results.

Prestige Consumer shares are trading lower after the company reported worse-than-expected Q4 financial results and issued weak guidance.

Ferroglobe Board Approves Share Buyback Program Pending Shareholder Vote; Seeks Authorization For $200M Repurchase Over 5 Years

WOOF

Petco Health And Wellness shares are trading higher. The company appointed Glenn Murphy as Executive Chairman of the Board of Directors, effective immediately.

Prestige Consumer Healthcare On May 6 Authorized Repurchase Of Up To $300M

In addition, the Board of Directors declared an initial quarterly cash dividend of $0.07 per share of the Company's common stock. The dividend is payable on June 12, 2024, to all stockholders of record as of May 29, 2024. The Company intends to pay dividends quarterly in the future, subject to market conditions and approval by the Board of Directors.

Dividends

JILL

J.Jill Initiates Quarterly Dividend Of $0.07 Per Share

Kintara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTRA#NASDAQ">KTRA</a>) reported quarterly losses of $(0.05) per share.

Kintara Therapeutics, Inc. - Common Stock

KTRA

Kintara Therapeutics Q3 2024 GAAP EPS $(0.05)

Guidance

Prestige Consumer Healthcare Sees FY25 Revenue Growth ~1%, EPS $4.40-$4.46 vs $4.62 Est.

ARQT

Arcutis Biotherapeutics shares are trading higher after the company reported better-than-expected Q1 financial results.

MP Materials (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MP#NYSE">MP</a>) underwent analysis by 10 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $22.35, a high estimate of $30.00, and a low estimate of $15.00. A 11.76% drop is evident in the current average compared to the previous average price target of $25.33. 
<img src="https://www.benzinga.com/files/images/story/2024/1715720471_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The standing of MP Materials among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subash Chandra</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$30.00</td>
<td>-</td>
</tr>
<tr>
<td>Subash Chandra</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$30.00</td>
<td>-</td>
</tr>
<tr>
<td>Tyler Langton</td>
<td>JP Morgan</td>
<td>Announces</td>
<td>Neutral</td>
<td>$16.00</td>
<td>-</td>
</tr>
<tr>
<td>Corinne Blanchard</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Hold</td>
<td>$15.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Laurence Alexander</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$28.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>George Gianarikas</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$22.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Carlos De Alba</td>
<td>Morgan Stanley</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$15.50</td>
<td>-</td>
</tr>
<tr>
<td>Lawson Winder</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$25.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Tyler Langton</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$20.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Tyler Langton</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$22.00</td>
<td>$24.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to MP Materials. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of MP Materials compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of MP Materials's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of MP Materials's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/MP/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on MP Materials analyst ratings.</a>
<h2>Delving into MP Materials's Background</h2>
MP Materials Corp is the producer of rare earth materials in the Western Hemisphere. The company owns and operates the Mountain Pass Rare Earth Mine and Processing Facility, the only rare earth mining and processing site of scale in North America.
<h3>A Deep Dive into MP Materials's Financials</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Decline in Revenue: Over the 3 months period, MP Materials faced challenges, resulting in a decline of approximately -49.13% in revenue growth as of 31 March, 2024. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Materials sector.
Net Margin: MP Materials's net margin excels beyond industry benchmarks, reaching 33.87%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): MP Materials's ROE excels beyond industry benchmarks, reaching 1.32%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): MP Materials's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.7% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: MP Materials's debt-to-equity ratio stands notably higher than the industry average, reaching 0.83. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>How Are Analyst Ratings Determined?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Critical Insights From MP Materials Analyst Ratings: What You Need To Know

Prestige Consumer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBH#NYSE">PBH</a>) reported quarterly earnings of $1.02 per share which missed the analyst consensus estimate of $1.14 by 10.53 percent. The company reported quarterly sales of $277.00 million which missed the analyst consensus estimate of $287.47 million by 3.64 percent. This is a 3.10 percent decrease over sales of $285.87 million the same period last year.

Earnings Misses

Prestige Consumer Q4 2024 Adj EPS $1.02 Misses $1.14 Estimate, Sales $277.00M Miss $287.47M Estimate

SDRL

Seadrill shares are trading higher after the company reported better-than-expected Q1 GAAP EPS results.

Sony Group Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SONY#NYSE">SONY</a>) has announced that &#8220;Helldivers 2&#8221; sold over 12 million copies in its first 12 weeks, making it <a href="https://www.benzinga.com/general/gaming/24/02/37015019/this-game-outperformed-call-of-duty-and-palworld-on-steam-a-look-at-sonys-first-simultaneous-ps5-a">PlayStation&#8217;s fastest-selling game ever. </a>
During an investor call, Sony noted that the live-service shooter for PlayStation 5 and PC &#8220;far exceeded&#8221; expectations, reaching this milestone by May 5, 2024, IGN <a href="https://www.ign.com/articles/helldivers-2-is-playstations-fastest-selling-game-of-all-time-with-over-12-million-sold-in-12-weeks">reported.</a>
This surpasses the record previously held by <a href="https://www.benzinga.com/general/gaming/24/05/38769512/playstation-exclusive-god-of-war-ragnarok-reportedly-set-for-pc-release">&#8220;God of War Ragnarok,&#8221;</a> which sold 11 million copies within 75 days of its release in November 2022.
See Also: <a href="https://www.benzinga.com/general/gaming/24/05/38652023/community-outrage-forces-playstation-to-reverse-helldivers-2-account-linking-requirement">Community Outrage Forces PlayStation To Reverse Helldivers 2 Account Linking Requirement</a>
&#8220;Helldivers 2&#8221; launched simultaneously on PC and PS5 with cross-play capabilities, significantly boosting its co-op PVE action. The game is described as Sony&#8217;s biggest PC hit to date, contributing &#8220;significantly&#8221; to the company's sales and profits last quarter. 
Despite its $39.99 price tag, &#8220;Helldivers 2&#8221; quickly gained popularity, initially causing server issues due to the high volume of players. It became one of the most-played games on Steam, peaking at 458,709 concurrent players. Although Sony did not release PS5 concurrent player numbers, the game&#8217;s popularity was clear.
The success of &#8220;Helldivers 2&#8221; might prompt Sony to release more multiplayer games simultaneously on PC and PS5 and consider more budget pricing, as demonstrated by the game&#8217;s success at $39.99. Upcoming titles like &#8220;Concord,&#8221; a PVP multiplayer FPS from Firewalk Studios set for release in 2024, might follow this model.
<a href="https://www.benzinga.com/general/gaming/24/02/37219923/helldivers-2-ceos-honesty-shines-as-game-hits-409k-players-on-steam-get-it-later">Arrowhead CEO Johan Pilestedt</a> expressed his amazement on Twitter, stating: "It's crazy to think that there are more Helldivers than there are Swedes." The developer plans to expand &#8220;Helldivers 2&#8221; with new content throughout 2024, including new vehicles and a third enemy faction.
Read Next: <a href="https://www.benzinga.com/general/gaming/24/03/37519131/helldivers-2-developer-refutes-sony-acquisition-speculation-we-are-independently-owned">Helldivers 2 Developer Refutes Sony Acquisition Speculation: &#8216;We Are Independently Owned&#8217;</a>
Image credits: Arrowhead Game Studios via Steam.

Gaming

SONY

Helldivers 2: PlayStation's New 'Reigning Champ' In Fastest-Selling Games, Beats This Iconic Title

Copart (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRT#NASDAQ">CPRT</a>) has outperformed the market over the past 10 years by 17.52% on an annualized basis producing an average annual return of 28.32%. Currently, Copart has a market capitalization of $52.30 billion. 
Buying $100 In CPRT: If an investor had bought $100 of CPRT stock 10 years ago, it would be worth $1,191.68 today based on a price of $54.40 for CPRT at the time of writing.
<h3>Copart's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1715720423_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CPRT

$100 Invested In This Stock 10 Years Ago Would Be Worth $1,200 Today

T-Mobile US (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>) has outperformed the market over the past 5 years by 2.71% on an annualized basis producing an average annual return of 15.71%. Currently, T-Mobile US has a market capitalization of $189.59 billion. 
Buying $100 In TMUS: If an investor had bought $100 of TMUS stock 5 years ago, it would be worth $215.48 today based on a price of $161.79 for TMUS at the time of writing.
<h3>T-Mobile US's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1715720418_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

TMUS

$100 Invested In T-Mobile US 5 Years Ago Would Be Worth This Much Today

Contango Ore (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CTGO#AMEX">CTGO</a>) reported quarterly losses of $(2.14) per share which missed the analyst consensus estimate of $(0.82) by 160.98 percent.

CTGO

Contango Ore Q3 2024 GAAP EPS $(2.14)

Nextracker shares are trading higher after the company reported better-than-expected Q4 financial results.

Streaming company Roku Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>) announced a new multi-year deal with Major League Baseball that expands its sports carriage ambitions.
What Happened: Roku signed a new deal to carry Sunday Leadoff live games starting May 19, bringing <a href="https://editorial.benzinga.com/wp-admin/post.php?post=338073&amp;action=edit">Major League Baseball </a>content to its users for free.
According to Roku, the <a href="https://newsroom.roku.com/news/2024/05/roku-lands-exclusive-rights-to-major-league-baseball-sunday-leadoff/tetn-dag-1715620860">deal </a>is exclusive and signed as a multi-year deal.
The games will air for free on The Roku Channel along with a new MLB Zone that highlights live and upcoming games, nightly recaps and highlights.
This partnership makes Roku the home for the first games on most Sundays during the season.
"As television programming, live sports and the leagues have fragmented across networks, apps and multiple packages, Roku — home to all of them — plays an increasingly crucial role for viewers and advertisers," Roku Media President Charlie Collier said.
Collier added that the deal gives Roku weekly Sunday MLB content and 24/7 baseball curation.
"The lead-in to all of television is now the lead-off for Sunday baseball as well. It's a terrific partnership."
Sunday Leadoff games stream every Sunday from May 19 to Sept. 15 beginning with a matchup of the Boston Red Sox and St. Louis Cardinals at 1:05 p.m. ET on May 19.
"Since Roku serves as an entertainment gateway for millions, this partnership offers a valuable new promotional and distribution platform for MLB games and content," MLB Deputy Commissioner, Business and Media Noah Garden said.
Related Link: <a href="https://www.benzinga.com/news/earnings/24/04/38446113/roku-exceeds-q1-earnings-expectations-provides-upbeat-guidance">Roku Exceeds Q1 Earnings Expectations, Provides Upbeat Guidance</a>
Why It's Important: The Roku Channel reaches 120 million people in the U.S., according to the company.
Once mostly a hardware company that streamed other partners' channels and apps, Roku has grown its original programming through The Roku Channel. The move could help provide a boost to advertising revenue and lessen the dependence on other partners.
The Sunday kickoff game was previously part of a package for Peacock, the streaming platform owned by Comcast Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCSA#NASDAQ">CMCSA</a>). The deal with Comcast ended at the conclusion of the 2023 MLB season.
Roku <a href="https://www.benzinga.com/markets/equities/24/04/38073726/whats-going-on-with-roku-shares-after-partnering-national-basketball-association">signed a deal </a>with the National Basketball Association for the NBA Fast channel and NBA Zone.
In June 2023, Roku<a href="https://www.benzinga.com/general/entertainment/23/06/33029348/roku-joins-the-live-sports-streaming-race-grabs-rights-to-this-sport"> signed a deal</a> to be the official streaming home of Formula E races, marking its first-ever live sports partnership.
The push into live sports could help boost advertising revenue for Roku as sports have often led the way in advertising and are more resistant to consumers watching on-demand versus live.
More sports leagues continue to carve out additional rights packages for specific days of the week or aimed at streaming companies, which could benefit Roku if it stays aggressive in pursuing additional live sports content. 
 ROKU Price Action: Roku shares were up 3.49% to $62.26 at market close on Tuesday versus a 52-week trading range of $51.62 to $108.84.
Read Next: <a href="https://www.benzinga.com/general/entertainment/24/05/38742764/more-money-more-streams-netflix-disney-appletv-and-hulu-see-higher-usage-among-wealthier-am">More Money, More Streams: Netflix, Disney+, AppleTV+ And Hulu See Higher Usage Among Wealthier Americans</a>
Photo: Courtesy Roku<a href="https://variety.com/lists/tv-ad-sales-leaders-upfront/"></a>

Sports

Media

CMCSA

ROKU

Roku Dives Deeper Into Live Sports: Is New MLB Partnership A Home Run?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Eliem Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/elym-stock-quote/">ELYM</a>) just reported results for the fourth quarter of 2023.<ul><li>Eliem Therapeutics reported earnings per share of -13 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/04/elym-stock-earnings-eliem-therapeutics-for-q4-of-2023/">ELYM Stock Earnings: Eliem Therapeutics Reported Results for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

ELYM Stock Earnings: Eliem Therapeutics Reported Results for Q4 2023

Eliem Therapeutics to buy Tenet, announces $120 million private placement

Eliem Therapeutics (ELYM) has issued an update. Eliem Therapeutics, Inc. has entered into an Acquisition Agreement to take over Tenet Medicines, In...

Eliem Therapeutics Expands with Tenet Medicines Acquisition

NKTR, VERU and EGIO among mid-day movers

GLYC, APLD and AUTL are among after hour movers

LPCN, ADIL and CADL among pre-market losers

HROW, HCAT and EGRX are among after hour movers

Annovis Bio, Cyclacel Pharmaceuticals, Biodexa Pharmaceuticals among healthcare movers

BKKT, CETX and SWVL among mid-day movers

RCAT, SMFL and NUVO among mid-day movers

ADIL

ANVS

APLD

AUTL

AWIN

BATL

BDRX

BSGM

BTOG

CURI

EGIO

EGRX

GCTS

GLYC

HCAT

HRMY

HROW

HYMC

IPDN

IRON

LIFW

LPCN

LYEL

MDIA

MGRM

MNDR

MRVI

NKTR

NUVO

PYXS

RCAT

SCRM

SMFL

TERN

TRDA

VERU

VVPR

Economics

Press Releases

Eliem Therapeutics Announces Plans to Explore Strategic Alternatives

Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement

ELYM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Eliem Therapeutics, Inc. Is Fair to Shareholders

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALPN, ELYM, MODN

Kuehn Law Encourages ALPN, JBT, ELYM, and HRT Investors to Contact Law Firm

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MODN, ALPN, ELYM, JBT

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Eliem Therapeutics, Inc. (ELYM) and Encourages Investors to Contact the Firm

Legal

Kuehn Law Encourages INRD, AIRC, ELYM, and ALPN Investors to Contact Law Firm

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates INRD, AIRC, ELYM, ALPN

AIRC

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Eliem Therapeutics Stock (NASDAQ:ELYM), Short Interest Report

People Also Watch